Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

Authors not listed

Eli Lilly and Company · 2016

Abstract

The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2016). A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease. <em>Eli Lilly and Company</em>. https://clinicaltrials.gov/study/NCT02760602
Vancouver
Anonymous. A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease. Eli Lilly and Company. 2016.
BibTeX
@misc{anon2016AMonth, title = {A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease}, author = {Anonymous}, journal = {Eli Lilly and Company}, year = {2016}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings